Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

BACKGROUND: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC. METHOD...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Santoni, M, De Giorgi, U, Iacovelli, R, Conti, A, Burattini, L, Rossi, L, Luca Burgio, S, Berardi, R, Muzzonigro, G, Cortesi, E, Amadori, D, Cascinu, S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2013
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790174/
https://ncbi.nlm.nih.gov/pubmed/24008663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.522
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items